• / Free eNewsletters & Magazine
  • / My Account
Home>Research & Insights>Investment Insights>Apple Turns Sour for Some Big Funds

Related Content

  1. Videos
  2. Articles
  1. Which 'Blue-Chip' Fund Deals a Better Hand?

    Morningstar's Katie Reichart compares the Blue Chip Growth funds offered by T. Rowe Price and Fidelity .

  2. Fidelity's 2012 Leaders and Laggards

    Relative to their categories, Fidelity's stock funds generally fared better than its fixed-income portfolios last year, but several funds in both camps have good long-term prospects.

  3. Top Bond-Fund Picks for Retirees

    Morningstar's Eric Jacobson runs the gamut with some of his favorite fixed-income funds, including ideas for core, short-term, multisector, high-yield, and muni exposure.

  4. 4 High-Profile Manager Changes

    What to make of recent changes at T. Rowe Price, Fidelity , Artisan, and First Eagle.

Apple Turns Sour for Some Big Funds

Here's a look at how Apple's fourth-quarter retreat has affected some widely held, actively managed stock funds.

Dan Culloton, 01/10/2013

About nine months ago, I noted that Apple AAPL had been "among the biggest factors explaining the difference between top- and bottom-performing large-blend and -growth funds for the year to date as well as the trailing 12-month and trailing three-year periods."

That's still true. Since the worm turned for Apple in September, however, we've seen just how much some funds had relied on the technology giant for their results.

Apple was a juggernaut for most of 2012, rising 33%, making it by far the biggest contributor to the returns of funds that had made substantial commitments to the stock--including some of the largest and most widely held funds in the industry.

Then September happened. Chalk it up to concerns about increasing competition in the tablet and mobile phone markets, efforts to realize substantial capital gains before taxes increased this year, or just reversion to the mean for a stock that had delivered above-average results for a long time. Nonetheless, Apple took a tumble. From Sept. 19, 2012, through Jan. 8, 2013, the stock shed nearly a fourth of its value, taking down many portfolios that had above-average holdings in the maker of the iPhone, iPad, iMac, and iWhatever-is-next. In the long term, this time period may amount to no more than a blip on Apple's and these funds' records. However, curiosity about how some of the industry's largest funds with big helpings of Apple have handled the stock's recent slide drove me to take a deeper look.

Big Bites of Apple
As one might expect, the typical technology-sector fund, which can hardly avoid having Apple among its top holdings, has lost about 3% since September. Most non-technology-sector funds with double-digit commitments to Apple also have taken it on the chin. Below is a list of the non-sector funds with the biggest allocations to Apple as of their most recent portfolios. All of them had double-digit stakes, and most have done worse than their benchmarks and peers since Apple's September peak through Jan. 8, 2013. But the big Apple stakes didn't help many of the listed portfolios outperform before the stock stumbled at the end of the third quarter either, suggesting something was probably amiss elsewhere in their portfolios. Meanwhile, Janus Twenty D JNTFX, Janus Forty JDCAX, and Matthew 25 MXXVX posted top-decile returns in 2012, but most of that seemed to come before Apple's apex, since they have been weaker since then. This indicates that a good portion of their good returns relied on Apple.

Apple Bites Big Funds
More widely held funds with bigger asset bases haven't been immune from Apple's recent contraction. Three of the 10 largest funds with the biggest helpings of Apple have lagged their benchmarks and peers since the peak: Fidelity Growth Company FDGRX, Harbor Capital Appreciation HACAX, and Fidelity Blue Chip Growth FBGRX. Apple has by far been the biggest detractor to their returns, but they also suffered the relative lack of industrial, consumer cyclical, and financial stocks, such as rebounding banks like Citigroup C; these names were present to a greater degree in some other large funds that have fared better in recent months.

Four of the industry's largest funds with Apple overweighting relative to the broad market have failed to beat their respective categories since Apple's recent top but have beaten the Russell 1000 Growth Index: MainStay Large Cap Growth A MLAAX, Fidelity Advisor New Insights FNIAX, and Fidelity Contrafund FCNTX (which are near-clones), and T. Rowe Price Growth Stock PRGFX.

Three big funds with big Apple stakes have beaten both the Russell 1000 Growth Index and peers since Apple's peak: T. Rowe Price Blue Chip Growth TRBCX, Fidelity Series All-Sector Equity FSAEX, and Fidelity Magellan FMAGX. Apple's fall has stung these funds, to be sure, but gains in financials, consumer cyclicals, and industrials compensated for the losses. Starbucks SBUX and Precision Castparts PCP helped T. Rowe Price Blue Chip Growth, for example, while Citigroup buoyed Fidelity Magellan.


Among the larger, more growth-oriented funds with lower-than-average stakes in Apple, Vanguard Primecap VPMCX, American Funds Growth Fund of America AGTHX, American Funds AMCAP AMCPX, and American Funds Fundamental Investors ANCFX have beaten both the S&P 500 and the Russell 1000 Growth benchmarks as well as peers since the stock's peak.

Apple is not as widely held among big value funds, so it's not surprising Dodge & Cox Stock DODGX and Vanguard Windsor II largely sat out Apple's rise and recent fall. Some value-oriented funds do own a smaller stakes in Apple, though. This includes American Funds Washington Mutual AWSHX, which lagged its benchmark and peers in both the nine months leading to Apple's turnabout and after. The fund's focus on more staid dividend-growth stocks in the midst of a decent rally would seem to have more to do with its recent modest return than Apple.

No Apple, No Problem
Fidelity Low-Priced Stock FLPSX owns no Apple and probably wouldn't have anyway. It's been a long time since the price was low enough for a fund that tries to buy mostly mid- and small-cap stocks when their share prices are under $35. Fidelity Low-Priced Stock continues to march to its own drummer, beating its category and most relevant benchmarks.

Finally, the three Apple-abstaining funds that I highlighted back in April 2012--Mairs & Power Growth MPGFX, Oakmark Select OAKLX, and BBH Core Select BBTEX--continue to post solid benchmark- and peer-beating gains independent of the domestic market's most valuable stock. Indeed, the managers of all three funds were nominees for Morningstar's 2012 Domestic-Stock Fund Manager of the Year (as was Steve Wymer of the aforementioned Fidelity Growth Company), and Mairs & Power's Bill Frels and Mark Henneman won the award.

Apple has been both David and Goliath in the past year. It has seemed like an unstoppable growth and innovation machine that money managers ignored only at their peril. It also has been derided as a much-too-loved "story stock" destined to see its margins eroded by competition and its share price pared by a reversion to the mean. No matter which way Apple goes in the future, its presence or absence will continue to influence large-cap portfolios. Fund investors need to both understand and be comfortable with their managers' decisions regarding the stock. More broadly, investors should recognize that funds that thrive by a big commitment to a company like Apple also can struggle because of it.


Dan Culloton owns shares of American Funds Washington Mutual as well as Dodge & Cox International and Primecap Odyssey Aggressive Growth, which are run by managers who run funds mentioned in this article.

Dan Culloton is an associate director of fund analysis for Morningstar and editor of Morningstar's Vanguard Fund Family Report, a monthly newsletter that offers independent, no-holds-barred guidance on the pros and cons of this dominant fund family. Click here for a free issue of the Vanguard Fund Family Report.

©2017 Morningstar Advisor. All right reserved.